The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
webdev2020 年 2 月 19 日
Getting started with in-house development: how does it work?
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020 年 2 月 10 日
How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive…
webdev2020 年 1 月 24 日
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
webdev2020 年 1 月 17 日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019 年 12 月 19 日
Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates
Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia,…
Certara2019 年 11 月 11 日
